(CercleFinance.com) – Sanofi will reduce by 78% the list price in the United States of Lantus (insulin glargine injection) 100 units/ml, Sanofi’s most prescribed insulin in the United States.
The company will also set a $35 cap on the remainder to be paid by Lantus for all patients who have health insurance.
‘ These measures, which will come into effect on January 1, 2024, will be in addition to decisions already taken in June 2022 to reduce the cost of diabetes medicines. The launch of a biosimilar of Lantus at a price reduced by 60% compared to its list price and the capping of the remaining insulin charge at 35 dollars for all people without insurance ‘indicates the group.
Sanofi will also reduce the list price of its short-acting insulin Apidra (insulin glulisine injection) 100 units/ml by 70%.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
